The Dual Specificity Mitogen Activated Protein Kinase Kinase 2 pipeline drugs market research report outlays comprehensive information on the Dual Specificity Mitogen Activated Protein Kinase Kinase 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Dual Specificity Mitogen Activated Protein Kinase Kinase 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Genetic Disorders, Non Malignant Disorders, and Central Nervous System which include the indications Solid Tumor, Low-Grade Glioma, Neurofibromatoses Type I (Von Recklinghausen’s Disease), Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Plexiform Neurofibroma, Schwannoma, Neurodegenerative Diseases, and Alzheimer’s Disease. It also reviews key players involved in Dual Specificity Mitogen Activated Protein Kinase Kinase 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Dual Specificity Mitogen Activated Protein Kinase Kinase 2 pipeline targets constitutes close to 19 molecules. Out of which, approximately 19 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 2, 5, 6, 2, 2, and 2 respectively.
Dual Specificity Mitogen Activated Protein Kinase Kinase 2 overview
MAP2K2 is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, cognitive disability, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax.
For a complete picture of Dual Specificity Mitogen Activated Protein Kinase Kinase 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
